Shares of GeneDx Holdings (NASDAQ: WGS) are soaring 5.58% in intraday trading on Friday, following the release of its impressive first-quarter 2025 financial results. The genetic testing company reported better-than-expected earnings and revenue figures, signaling strong growth and improved financial health.
GeneDx's Q1 2025 report showcased significant year-over-year improvements. The company's revenue surged 40% to $87.1 million, surpassing analyst estimates by 9.2%. Additionally, GeneDx's net loss narrowed by 68%, with the loss per share improving from $0.78 in Q1 2024 to $0.23 in Q1 2025, beating analyst expectations by 4.2%.
Investors appear encouraged by GeneDx's financial progress and future prospects. The company's revenue is forecast to grow at an average of 14% per annum over the next three years, outpacing the 7% growth projected for the US Healthcare industry. This positive outlook, combined with the strong Q1 performance, has likely fueled today's stock price surge, as the market reassesses GeneDx's potential in the competitive genetic testing landscape.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。